Samsung Biologics to Supply Moderna Vaccine 'Contract Manufacturing' Domestically for the First Time Tomorrow

[Image source=Yonhap News]

[Asia Economy Reporter Kim Daehyun] Moderna's COVID-19 vaccine, contract-manufactured by Samsung Biologics, will be supplied domestically for the first time.

On the 27th, the Ministry of Health and Welfare announced that it will hold a shipment ceremony at Samsung Biologics in Yeonsu-gu, Incheon at 8:30 a.m. on the 28th, revealing the process of shipping the Moderna vaccine. The vaccines shipped from Samsung Biologics on that day are part of the 2,435,000 doses allocated for domestic supply.

The government stated on the 26th that Samsung Biologics plans to supply the initial batch (PPQ) domestically within this week.

The Moderna vaccine contract-manufactured by Samsung Biologics will be widely used for new vaccinations in the fourth quarter, second doses, and additional vaccinations (booster shots) for high-risk groups. Until now, all Moderna vaccines administered domestically were products manufactured overseas.

The shipment ceremony will be attended by Minister of Health and Welfare Kwon Deok-cheol, Deputy Director of the Korea Disease Control and Prevention Agency Kim Heon-ju, Head of the Transport Support Headquarters Park Joo-kyung, Director of the Gyeongin Regional Food and Drug Administration Woo Young-taek, Democratic Party leader Song Young-gil, and Samsung Biologics CEO John Rim.

This content was produced with the assistance of AI translation services.